EXPLORATORY-STUDY OF THE DECONGESTIVE EFFECT OF RHINOPRONT SYRUP IN ADULTS AND IN CHILDREN WITH ACUTE RHINITIS

The decongestive effect of Rhinopront syrup was assessed in 18 adults and 18 children with acute rhinitis, by comparison to a matching place bo syrup and to a commercial standard decongestant (Triaminic tablets or drops). The evolution of symptoms following single dose administrat ion of each treatment was estimated both by objective measurements of nasal resistance using bilateral rhinomanometry and by subjective eval uation of nasal congestion and aspect of the mucosa. In children, the treatment was continued over the next 4 days and the global clinical e fficacy of the formulations was subjectively evaluated by the parents. In adult patients, a significant decrease in nasal resistance was obt ained after a single dose of Rhinopront (15 g). The effect was already important after 0.5 h and reached a minimum of approximate to 50% of baseline within 1 to 2 h; the drop in nasal resistance was significant ly less intense for Triaminic (p < 0.05; 0.5-1-h period) and for the p lacebo (p < 0.05; 0.5-2-h period). In children, the scatter of rhinoma nometric measurements precluded the observation of any significant wit hin- or between-group differences; however, a significantly lower nasa l congestion score was observed for Rhinopront than placebo, between 4 and 10 h after single dose administration (1 g per year of age). The present work suggests that Rhinopront is an effective nasal decongesta nt in adults and children with acute congestive rhinitis and supports the adequacy of the proposed twice-daily dosing rate.